| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Antigenics, Inc. |
| 630 Fifth Avenue, Suite 2100, New York, NY 10111 * (212) 332-4774 |
| Business Description | The company is engaged in the discovery and development of a family of novel immunotherapeutics for the treatment of life threatening and chronic medical conditions. |
| Offering Information Company has | |||
| Trading As | AGEN (NASNTL) | Industry | Pharmaceutical (SIC 2836) |
| Type of Stock Offered | Common Shares | Filing Date | 11/30/99 |
| Domestic Shares Offered | 3,500,000 | Offer Date | 2/3/00 |
| Foreign Shares Offered | 0 | Filing Range | $14.00 - $16.00 |
| Company Shares | 3,500,000 | Offer Price | $18.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.260 |
| Gross Proceeds | $63,000,000 | Selling | $0.750 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | - - | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| U.S. Bancorp Piper Jaffray | Lead Manager | (612) 342-6220 |
| Robertson, Stephens & Company | Co-manager | (415) 989-8500 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/94 | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 9/30/98 | 9/30/99 |
| Revenues | - | - | - | - | - | - | - |
| Income from Oper. | -0.183 | -3.235 | -2.690 | -4.125 | -9.003 | -6.168 | -17.806 |
| Net Income | -0.183 | -3.227 | -2.159 | -3.644 | -8.267 | -5.588 | -28.468 |
| E.P.S | - | - | - | - | - | - | - |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -6.38 | - | - | ||||
| Cash Flow - Inv. | -3.68 | - | - | ||||
| Cash Flow - Fin. | 19.13 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/99 | Financial Ratios | ||||
| Total Assets | 21.28 | Current Assets | 13.23 | Current Ratio | 6.09 |
| Total Liab. | 4.54 | Current Liab. | 2.17 | Debt Ratio | 21.33% |
| Total Equity | 16.74 | Working Cap. | 11.06 | Debt to Equity Ratio | 0.27 |
| Cash | 12.61 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to fund clinical trials; to fund research and development of our immunotherapeutics; to increase our manufacturing capacity; and for general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Palmer & Dodge |
| Bank's Law Firm | Shearman & Sterling |
| Registrar/Transfer Agent | American Stock Transfer & Trust Co |
| Auditor | KPMG LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Oracle Partners LP | ||
| Note: represents ownership of 5% or more prior to the offering. | ||